PF-06648671
Sponsors
Pfizer
Conditions
HealthyHealthy Adult Subjects and Healthy Elderly SubjectsHealthy Subjects
Phase 1
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
CompletedNCT02316756
Start: 2014-12-31End: 2015-03-31Updated: 2015-06-09
A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)
CompletedNCT02407353
Start: 2015-10-31End: 2016-03-31Updated: 2016-03-22
A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects
CompletedNCT02440100
Start: 2015-05-31End: 2016-10-31Target: 92Updated: 2016-11-10
An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.
CompletedNCT02883114
Start: 2016-09-30End: 2016-11-30Updated: 2016-12-20